前收市價 | 4.8500 |
開市 | 4.8400 |
買盤 | 4.7400 x 200 |
賣出價 | 4.7900 x 200 |
今日波幅 | 4.7600 - 4.9450 |
52 週波幅 | 3.5300 - 11.3600 |
成交量 | |
平均成交量 | 8,628,157 |
市值 | 668.975M |
Beta 值 (5 年,每月) | 1.58 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -5.4100 |
業績公佈日 | 2024年5月07日 - 2024年5月13日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 15.40 |
Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID vaccine induces a more robust immune response compared with its previously approved bivalent COVID vaccine.
For this biotech, a rebound seems far too unlikely.
There’s a simple reason why short-squeeze stocks to buy represent a powerful catalyst: they’re intuitive and easier to engage. Buying something and hoping that it appreciates in value represents an organically sensible strategy. It’s the reason why people collect everything from baseball cards to luxury Swiss watches. Stated differently, it doesn’t take much to explain the rationale behind short-squeeze stocks to buy. On the other hand, shorting a stock represents an incredibly complex affair by